Tumor Mutational Burden Predicts the Outcome of Patients With Muscle-invasive bladder Cancer Undergoing Immune-checkpoint Inhibitor-Based Neoadjuvant Therapy.

Chiara Mercinelli¹, Giuseppe Basile², Giovanni L Pastorino³, Antonio Cigliola³, Brigida A Maiorano⁴, Valentina Tateo⁴, Michela Piacentini⁴, Debora Serafin⁵, Gualtiero Guandalini³, Roberta Lacava⁴, Gaia Latini⁴, Maurizio Colecchia⁶, Alberto Briganti⁷, Marco Moschini⁸, Francesco Montorsi⁷, Dean Pavlick⁹, Jeffrey S Ross¹⁰, Andrea Necchi³

¹Università Vita-Salute San Raffaele, Milan, Italy; Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy. Electronic address: mercinelli.chiara@hsr.it.

²Urology Department, The Royal Free London Foundation Trust, London, UK; Urology Department, IRCCS Ospedale San Raffaele, Milan, Italy.

³Università Vita-Salute San Raffaele, Milan, Italy; Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy.

⁴Medical Oncology Department, Comprehensive Cancer Center, IRCCS San Raffaele Hospital, Milan, Italy.

⁵Università Vita-Salute San Raffaele, Milan, Italy; Medical Oncology Unit 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.

⁶Università Vita-Salute San Raffaele, Milan, Italy; Department of Pathology and Laboratory Medicine, IRCCS Ospedale San Raffaele, Milan, Italy.

⁷Università Vita-Salute San Raffaele, Milan, Italy; Urology Department, IRCCS Ospedale San Raffaele, Milan, Italy.

⁸Urology Department, IRCCS Ospedale San Raffaele, Milan, Italy.

⁹Foundation Medicine Inc, Cambridge, MA.

¹⁰Foundation Medicine Inc, Cambridge, MA; Upstate Medical University, Syracuse, NY.

PubMed DOI

Abstract

INTRODUCTION: Immune checkpoint inhibitors (ICI) have demonstrated meaningful activity as neoadjuvant therapy in muscle-invasive bladder cancer (MIBC). Identifying patients most likely to respond to ICI-based neoadjuvant strategies remains an unmet need. MATERIALS AND METHODS: Tumor mutational burden (TMB) from baseline transurethral resection of bladder (TURB) tumor samples of MIBC patients trea…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.